The role of nocebo effects in identifying patients at risk for pain progression in fibromyalgia - Nocebo effects in fibromyalgia pain progression

niversiteit Leiden0 个研究点目标入组 75 人开始时间: 待定最近更新: 2024年4月15日

适应症

试验速览

暂无简介。

•For patients:
•Physical conditions other than fibromyalgia explaining pain symptoms
•Psychiatric conditions not related to fibromyalgia symptoms (e.g.,
•schizophrenia)
•Use of painkillers different than usual dose of treatment on the day of
•experimentation*
•For healthy controls:
•Chronic pain complaints (>=3 months) in the past or present or a diagnosis of
•fibromyalgia
•Severe physical or psychiatric co-morbidities that may interfere with the study
•protocol (e.g., DSM-V diagnosis)
•Current pain (>=3/10 on the Numeric Rating Scale) on the day of experimentation*
•Use of painkillers within 24 hours before the day of experimentation*
•Common criteria for both groups:
•Pregnancy or lactation
•Color blindness
•Injuries/open wounds on the non-dominant hand or arm*
•Carrying a pacemaker/implanted pumps
•Having implanted metals on the non-dominant hand or arm
•Refusal to remove artificial nails, nail polish, or any other substance
•covering the thumbnail*
•Unsuccessful pressure calibration, i.e., not being able to stably distinguish
•relevant pressure intensities
•*Exclusion criteria marked with a * pertain to the day of testing. In case one
•or more of these criteria are met at the day of testing, the appointment will
•be rescheduled if possible.

发起方

niversiteit Leiden